dc.contributor.author | Sæther, Sverre Georg | |
dc.contributor.author | Schou, Morten Brix | |
dc.contributor.author | Kondziella, Daniel | |
dc.date.accessioned | 2017-08-29T08:08:21Z | |
dc.date.available | 2017-08-29T08:08:21Z | |
dc.date.created | 2017-08-17T10:22:16Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1471-244X | |
dc.identifier.uri | http://hdl.handle.net/11250/2452155 | |
dc.description.abstract | Background:Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. Weaimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatricsymptoms in patients with and without paraneoplastic central nervous system syndromes.Methods:Eligible studies were selected from 1980 until February 2017 according to standardized review criteria andevaluated using Quality Assessment of Diagnostic Accuracy Studies−2 (QUADAS-2). We included studies describing thepsychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies inpatients with psychiatric disorders.Results:Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterizedonconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence incontrols was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Twocerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychoticand depressive syndromes, respectively.Conclusions:Theavailableevidencesuggeststhattheprevalenceofwell-characterized onconeural antibodies in patientswith psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in selectpatients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | BioMed Central | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.volume | 17 | nb_NO |
dc.source.journal | BMC Psychiatry | nb_NO |
dc.source.issue | 1 | nb_NO |
dc.identifier.doi | 10.1186/s12888-017-1325-z | |
dc.identifier.cristin | 1486831 | |
dc.description.localcode | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | nb_NO |
cristin.unitcode | 194,68,30,20 | |
cristin.unitcode | 194,65,30,0 | |
cristin.unitname | Institutt for helsevitenskap | |
cristin.unitname | Institutt for nevromedisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |